Article Details
Retrieved on: 2025-06-15 23:05:46
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Investment firm Piper Sandler has elevated Sutro Biopharma (STRO) from a Neutral to an Overweight rating, while maintaining a price target of $2.
Article found on: www.gurufocus.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here